Drug Trial Radar · NCT06688123
Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects
Last checked: Nov 20, 2026Latest source record: Jun 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
275
Actual
Start
Jan 8, 2025
Primary completion
Apr 22, 2026
Study completion Apr 22, 2026
Sponsor
- Lead sponsor
- Jiangsu HengRui Medicine Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Nov 14, 2024
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of SHR-3167 compared with insulin glargine after treatment in insulin naïve subjects with type 2 diabetes treated with metformin alone or in combination with SGLT2 subjects.
Conditions
- Type 2 Diabetes
Interventions
SHR-3167Drug
Dose level 1.
SHR-3167Drug
Dose level 2.
Insulin glargineDrug
Dose level 3.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change from baseline to week 20 in HbA1c (HemoglobinA1c)Time frame: Week 0 to week 20.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Jiangsu Provincial People's Hospital
Nanjing, Jiangsu, China
Shanghai Sixth People's Hospital
Shanghai, Shanghai Municipality, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.